0QFP Stock Chart & Stats
Ft11900.00
Ft0.00(0.00%)
At close: 4:00 PM EDT
Ft11900.00
Ft0.00(0.00%)
Day’s Range― - ―
52-Week RangeFt9,614.62 - Ft13,230.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.83K
Market Cap
Ft2.25T
Enterprise ValueFt1.94M
Total Cash (Recent Filing)Ft136.62B
Total Debt (Recent Filing)Ft21.74B
Price to Earnings (P/E)9.8
Beta0.21
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1306.92
Shares Outstanding186,374,860
10 Day Avg. Volume1,207
30 Day Avg. Volume1,834
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
Ft14,742.00Price Target Upside23.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chemical Works of Gedeon Richter News
0QFP FAQ
What was Chemical Works of Gedeon Richter Plc’s price range in the past 12 months?
Chemical Works of Gedeon Richter Plc lowest share price was Ft9614.62 and its highest was Ft13230.00 in the past 12 months.
What is Chemical Works of Gedeon Richter Plc’s market cap?
Chemical Works of Gedeon Richter Plc’s market cap is Ft2.25T.
When is Chemical Works of Gedeon Richter Plc’s upcoming earnings report date?
Chemical Works of Gedeon Richter Plc’s upcoming earnings report date is Nov 10, 2026 which is in 39 days.
How were Chemical Works of Gedeon Richter Plc’s earnings last quarter?
Chemical Works of Gedeon Richter Plc released its earnings results on Aug 07, 2026. The company reported Ft566 earnings per share for the quarter.
Is Chemical Works of Gedeon Richter Plc overvalued?
According to Wall Street analysts Chemical Works of Gedeon Richter Plc’s price is currently Undervalued.
Does Chemical Works of Gedeon Richter Plc pay dividends?
Chemical Works of Gedeon Richter Plc does not currently pay dividends.
What is Chemical Works of Gedeon Richter Plc’s EPS estimate?
Chemical Works of Gedeon Richter Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chemical Works of Gedeon Richter Plc have?
Chemical Works of Gedeon Richter Plc has 186,374,860 shares outstanding.
What happened to Chemical Works of Gedeon Richter Plc’s price movement after its last earnings report?
Chemical Works of Gedeon Richter Plc reported an EPS of Ft566 in its last earnings report. Following the earnings report the stock price went up 1.734%.
Which hedge fund is a major shareholder of Chemical Works of Gedeon Richter Plc?
Currently, no hedge funds are holding shares in GB:0QFP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemical Works of Gedeon Richter Plc
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
0QFP Company Deck
0QFP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong underlying operational progress: solid constant-currency revenue growth (8.7%), a significant 21% rise in Clean EBIT on a constant-currency basis, robust biotech and CNS performance, record free cash flow, and measurable cost/ESG benefits from API consolidation. However, reported results were meaningfully impacted by FX losses (notably >HUF 32bn in Q2), a weaker General Medicines performance affected by timing and market factors, one-off impairments in Biotech, and restructuring costs. On balance, the operational wins, upgraded Clean EBIT guidance, cash generation and pipeline progress outweigh the transitory negatives driven largely by FX and one-off items, supporting a constructive outlook.View all GB:0QFP earnings summaries0QFP Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
Ft14,742.00
▲(23.88% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Chemical Works of Gedeon Richter
―
Dr Reddy's Laboratories
―
Teva
―
Perrigo Company
―
AstraZeneca
―
Pfizer
―
GlaxoSmithKline
―









